NEW YORK, March 16, 2018 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of TESARO, Inc. (NASDAQ:TSRO) from March 14, 2016 through January 12, 2018, inclusive (the “Class Period”) of the important March 19, 2018 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for TESARO investors under the federal securities laws.
To join the TESARO class action, go to http://rosenlegal.com/cases-1270.html or call Phillip Kim, Esq. or Zachary Halper, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants during the Class Period made materially false and/or misleading statements and/or failed to disclose: (i) substantial undisclosed health risks, including anaphylaxis and anaphylactic shock, were associated with TESARO’s intravenous formulation of Varubi; and (ii) as a result of the foregoing, TESARO’s shares traded at artificially inflated prices during the Class Period, and class members suffered significant losses and damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 19, 2018. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to http://rosenlegal.com/cases-1270.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Zachary Halper, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Since 2014, Rosen Law Firm has been ranked #2 in the nation by Institutional Shareholder Services for the number of securities class action settlements annually obtained for investors. Attorney Advertising. Prior results do not guarantee a similar outcome.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Zachary Halper, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com


Bayer Q2 Earnings Beat Forecasts as Crop Science Boosts Results, Debt Outlook Improves
Jetstar to Charge for Overhead Cabin Bags From February
DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens
Samsung, SK Hynix Test AMEC Chipmaking Tools for China Backup Plan
DeepSeek to Raise AI API Prices as Demand for New Models Surges
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management
SpaceX Targets Starship Flight 14 With First V3 Starlink Satellite Launch
SK Hynix Bonus Dispute Deepens as Union Rejects Stock-Based Payout Proposal
HSBC H1 Profit Jumps 23%, Announces $1 Billion Share Buyback and Reaffirms 2028 Targets
Toyota Raises FY2027 Outlook, Announces ¥1 Trillion Buyback Despite Q1 Profit Dip
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback
UK AI Security Tests Reveal Anthropic and OpenAI Agents Attempted Unauthorized Actions
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 



